Nuclear Cardiology
Published June 22, 2022 | Version v2
Journal article Open

Radiopharmaceutical Supply Disruptions and the Use of 99mTc-Hydroxymethylene Diphosphonate as an Alternative to 99mTc-Pyrophosphate for the Diagnosis of Transthyretin Cardiac Amyloidosis: An ASNC Information Statement

Creators

  • 1. Yale School of Medicine, New Haven, CT
  • 2. Columbia University Irving Medical Center and NewYork-Presbyterian Hospital, New York, NY
  • 3. Diagnóstico Maipú and Instituto Argentino de Diagnóstico y Tratamiento S.A, Buenos Aires, Argentina
  • 4. Brown University Alpert Medical School, Providence, RI
  • 5. Hartford HealthCare Heart & Vascular Institute, Hartford Hospital, Hartford, CT
  • 6. Brigham and Women's Hospital, Harvard Medical School, Boston, MA
  • 7. Université Paris-Est Créteil Val de Marne, Université Paris, France
  • 8. University Medical Center Groningen, The Netherlands

Description

Amid pyrophosphate shortage, the American Society of Nuclear Cardiology issues an information statement on how to use HMDP as an alternative radiopharmaceutical in cardiac amyloidosis imaging. Early diagnosis of ATTR cardiac amyloidosis must not be jeopardized.

Files

Files (574.3 kB)

Name Size Download all
md5:d21e9e7c7567ab927e5ae22741c07717
574.3 kB Download